Boc-L-(苯丙)噻唑-4-甲酸甲酯的合成研究

本文分别以L-苯丙氨酸甲酯盐酸盐和叔丁氧羰基保护的L-苯丙氨酸为起始原料,经两种不同的合成路线,完成了Boc-L-(苯丙)噻唑-4-甲酸甲酯的合成。其中,第一条路线共五步反应,总收率18%;第二条路线共四步反应,总收率22%,两条路线所涉及的官能团转换和反应有:氨基Boc保护、酯基还原、羟基Parikh-Doering氧化,MnO_2氧化,N-甲氧基-N-甲酰胺化。     

(R)-4-氰基-3-羟基丁酸乙酯的合成

研究了一条新的路线用于他汀类药物的重要中间体(R)-4-氰基-3-羟基丁酸乙酯的合成. 以廉价、易得的L-(－)-苹果酸为起始原料, 经酯化、还原、溴代和氰化四步反应得到目标化合物(R)-4-氰基-3-羟基丁酸乙酯, 合成总收率为56.7%. 所有中间体和最终产物均由ESI-MS, 1H NMR和13C NMR光谱及比旋光度表征并与文献值比较. 该方法原料易得、操作简便、收率良好, 产物容易分离纯化, 是一条适合大规模制备(R)-4-氰基-3-羟基丁酸乙酯的新合成工艺路线.     

（R）-螺[4，5]癸-2，7-二酮的合成

从环己烯酮出发，经手性催化的Michael加成反应，Wolff重排反应延长碳链， 再利用重氮化合物的C-H插入反应，以8步反应28．5％的总收率合成了手性β，β '-螺二酮．在合成路线中手性中心的构型保持不变．在最后的检测中未发现另一对 映体，开始产生的手性中心在合成过程没有消旋化。     

5-甲基-4-[3-氯-4-(3-氟苄氧基)苯氨基]吡咯并三嗪-6-甲酸乙酯的合成及其抗肿瘤活性

以3-甲基-2-氰基吡咯-4-甲酸乙酯为原料,采用新的路线,经3步反应合成了5-甲基-4-[3-氯-4-(3-氟苄氧基)苯氨基]吡咯并[2,1-f][1,2,4]三嗪-6-甲酸乙酯。通过对其合成过程中的反应条件优化,使反应收率得以提高,三步反应总收率26.4%。借助核磁共振、质谱等检测手段对反应中间体和目标化合物进行了结构表征。通过对人系肿瘤细胞SW480、A549和A431生长抑制活性实验,表明所得目标化合物能够选择性抑制肿瘤细胞A431的增殖(IC50:2.62±1.82μM)。     

1,4,7,10-N,N,N,N.四(2-(4-(2-乙酰硫基乙氧基)苯氧基)乙基)-1,4,7,10-四氮杂环十二烷的合成研究

以对苄氧基苯酚为原料,经3步反应合成不对称的对苯二酚烷氧基化合物,并以此为原料,合成乙酰硫基修饰的cyclen四取代氢醌醚链化合物.该路线不仅反应条件温和,操作易行,且收率高,克服了文献报道的合成路线重复性差、收率低的缺点.关键中间体及目标化合物经~1H NMR、~(13)C NMR、MS、IR和元素分析表征.     

D-脯氨酸催化的(3S,4S)-4-氨基-3-羟基-5-苯基戊酸衍生物的合成

报道了一条合成(3S,4S)-4-氨基-3-羟基-5-苯基戊酸(Ahppa)衍生物的新路线。以氨基保护的L-苯丙氨酸为起始原料,依次经Weinreb胺缩合、还原、aldol缩合及溴仿4步反应合成了3个Ahppa衍生物,总收率5.8%~6.7%,其结构经¹H NMR, ¹³C NMR和ESI-MS确证。对反应条件进行了探讨,结果表明：催化剂D-脯氨酸用量对反应收率影响不大,对立体选择性影响较大;氨基上保护基体积较大有利于提高反应立体选择性。     

(R)-2-甲基-7-炔-辛酸的合成

以1,5-戊二醇为起始原料,用Evans手性助剂诱导的烷基化反应构造了C-2手性中心,用Ohira-Bestmann试剂制备了末端炔基,通过13步反应,合成了(R)-2-甲基-7-炔-辛酸,总收率为17.1%,e.e.值大于99%.     

1-(2,4-二氯苯基)-4-甲基-5-(4-氯苯基)吡唑-3-羧酸的新合成方法

研究了合成1-(2,4-二氯苯基)-4-甲基-5-(4-氯苯基)吡唑-3-羧酸的新方法.以价廉、易得的对氯苯甲醛为原料,经羟醛缩合、环合及氧化得目标化合物,合成总收率为50.6%.中间体及最终产物结构由1H NMR,MS确证.该方法步骤较少、操作简便、收率良好,是一条适合中试放大的新合成工艺路线.     

3-碘-5-甲基-1,5-苯并硫氮杂(艹卓)-4(5H)-酮的合成

以2-甲基硫代苯胺为原料,通过酰化反应、碘环化反应合成了3-碘-5-甲基-1,5-苯并硫氮杂(艹卓)-4(5H)-酮,总收率86.3%,其结构经NMR,IR和MS表征.     

(4R)-5,5-二甲基-4-苄硫甲基-2-噁唑烷酮的合成

以价廉易得的天然L-半胱氨酸为原料,经巯基保护、酯化、氨基保护、格氏反应及环化等5步反应,合成了一个新的手性助剂(4R)-5,5-二甲基-4-苄硫甲基-2-噁唑烷酮,总收率31%.产物结构经IR,~1H NMR,~(13)C NMR及MS表征.     

Total syntheses of beta-carboline alkaloids, (R)-(-)-pyridindolol K1, (R)-(-)-pyridindolol K2, and (R)-(-)-pyridindolol.

The total syntheses of beta-carboline alkaloids, (R)-(-)-pyridindolols (1, 5, and 6) are described. The two key steps involved are (1) a thermal electrocyclic reaction of the 3-alkenylindole-2-aldoxime 10 and (2) a thermal cyclization of 3-alkynylindole-2-aldoxime 11 to construct the beta-carboline N-oxides 8, which upon heating with acetic anhydride and sequential treatment with trifluoromethanesulfonic anhydride gave the triflates 18. The Stille coupling reaction of 18 with vinylstannane, followed by cleavage of MOM ether, afforded the 1-ethenyl-3-hydroxymethyl-beta-carboline (7a). Subsequent acetylation of 7a yielded the acetate 7b, which was subjected to the Sharpless asymmetric 1,2-dihydroxylation by AD-mix-beta to produce (R)-(-)-pyridindolol K2 (6). Selective acetylation of 6 was effected by Ac(2)O and collidine to form (R)-(-)-pyridindolol K1 (5). By contrast, hydrolysis of 6 provided (R)-(-)-pyridindolol (1).     

An Efficient Synthesis of Optically Pure (R)- and (S)-2-(aminomethyl)alanine ((R)- and (S)-ama) and (R)- and (S)-2-(aminomethyl)leucine ((R)- and (S)-aml)

An efficient synthesis of enantiomerically pure (R)- and (S)-2-(aminomethyl)alanine ((R)- and (S)-Ama) 1a and (R)- and (S)-2-(aminomethyl)leucine ((R)- and (S)-Aml) 1b is described (Schemes 1 and 2). Resolution of the racemic amino acids was achieved using L -phenylalanine cyclohexylamide ( 2 ) as chiral auxiliary. The free amino acids 1a, b were converted to the N^α-Boc,N^γ-Z-protected derivatives 11a, b (Scheme 3) ready for incorporation into peptides. Based on the three crystal structures of the diastereoisomeric peptides 8a, 8b , and 9b , the absolute configurations in both series were determined. β-Turn type-I geometries were observed for structures 8b and 9b , whereas 8a crystallized in an extended backbone conformation.     

Preparation of (R)-11-hydroxyaporphine directly from (R)-10,11-dihydroxyaporphine ((R)-apomorphine)

A Regioselective synthesis of (R)-11-hydroxyaporphine 2 directly from (R)-10,11-dihydroxyaporphine ((R)-apomorphine, 1 ) is described for the first time. The isopropylidene ketal ring of 10,11-(isopropyl-idenyldioxy)aporphine 5 obtained by the isopropylidenation of apomorphine was regioselectively opened by ten equivalents of trimethylaluminum to give (R)-10-hydroxy-11-tert-butyloxyaporphine 6 . The free 10-hydioxyl position of 6 was triflated with N-pbenyltrifluoromethanesulfonimide and potassium carbonate under reflux to give (R)-10-[(trifluoromethyl)sulfonyloxy]-11-tert-butyloxyaporphine 7 . The reduced product, 11-tert-butyloxyaporphine 8 was prepared from 7 by a palladium-catalyzed hydrogenolysis. The ether cleavage of (R)-11-tert-butyloxyaporphine with 48% hydrobromic acid afforded the desired (R)-11-hydroxyaporphine 2 in good yield.     

Straightforward synthesis of (R)-(-)-kjellmanianone

A direct route to enantiomerically pure (-)-kjellmanianone is reported. The synthesis involves a cerium-catalyzed alpha-hydroxylation and an enzyme-catalyzed procedure to resolve tertiary alcohols at key stages. The intermediate beta-oxo ester was alpha-hydroxylated to give good yields of racemic kjellmanianone. The resolution of the racemic material was achieved by enzymatic saponification, followed by a chemical decarboxylation sequence to give enantiopure (-)-kjellmanianone with 99 % ee. Bromination then afforded the (-)-bromo derivative, whose X-ray structure provided evidence for the R configuration of (-)-kjellmanianone.     

Determination of (S)-(-)-cathinone and its metabolites (R,S)-(-)-norephedrine and (R,R)-(-)-norpseudoephedrine in urine by high-performance liquid chromatography with photodiode-array detection.

A high-performance liquid chromatographic (HPLC) procedure with photodiode-array detection (DAD) is described for the determination of (S)-(-)-cathinone (S-CA) and its metabolites (R,S)-(-)-norephedrine (R-NE) and (R,R)-(-)-norpseudoephedrine (R-NPE) in urine. Extraction and clean-up of 1-ml urine samples were performed on a cyano-bonded solid-phase column using (+/-)-amphetamine as internal standard. The concentrated extracts were separated on a 3-microns ODS-1 column with acetonitrile-water-phosphoric acid-hexylamine as the mobile phase. Peak detection was done at 192 nm. The detection limits for S-CA and R-NE/R-NPE in urine were 50 and 25 ng/ml, respectively. The differentiation of the enantiomers of cathinone and norephedrine was achieved by derivatization with (S)-(-)-1-phenylethyl isocyanate to the corresponding diastereomers followed by HPLC-DAD on a 5-microns normal-phase column. The R and S enantiomers of norpseudoephedrine were determined by gas chromatography-mass spectrometry after on-column derivatization with (S)-(-)-N-trifluoroacetylprolyl chloride. Following a single oral dose of 0.5 mg/kg of S-CA, the concentrations found in urine ranged from 0.2 to 3.8 micrograms/ml of S-CA, from 7.2 to 46.0 micrograms/ml of R-NE and from 0.5 to 2.5 micrograms/ml of R-NPE.     

Modified synthesis of methyl (1R,2R,3E,5R)-3-(hydroxyimino)-5-methyl-2-(1-methylethyl)-cyclohexanecarboxylate from (R)-4-menthen-3-one

A modified stereospecific synthesis of potentially biologically and pharmacologically active methyl (1R,2R,3E,5R)-3-(hydroxyimino)-5-methyl-2-(1-methylethyl)cyclohexanecarboxylate from (R)-4-menthen-3-one was developed using sequential 1,4-conjugate addition of Norman reagent catalyzed by CuI?CBF₃?Et₂O?CCuCl₂ and ozonolysis?Creduction of the intermediate (R,R,R)-vinylmenthone by hydroxylamine hydrochloridein MeOH.     

由(S)-和( R )-天冬氨酸合成( R )-和(S)-(2-苄氧乙基)环氧乙烷的改良方法

苄氧乙基环氧乙烷;不对称合成;由(S)-和( R )-天冬氨酸合成( R )-和(S)-(2-苄氧乙基)环氧乙烷的改良方法